After decades of clinical breakthroughs, Dana-Farber has helped increase survival rates and new treatment options for children with cancer. Yet, childhood cancer is still the leading cause of disease-related death in children in the United States. To help overcome this challenge, Dana-Farber’s Pediatric Cancer Genetic Risk Program brings together a team of physicians, genetic counselors, and researchers to help manage all aspects of genetic cancer risk.
Join us on September 28 for a discussion about how Dana-Farber is leading the way in transforming the prevention and treatment of cancer in children. Our panelists will be joined by a patient family member with firsthand experience with this program. Register for this complimentary educational webinar below, which will include a live, interactive session for your questions.
Introduction by: Scott Armstrong, MD, PhD
Featuring: Lisa Diller, MD, Junne Kamihara, MD, PhD, Jaclyn Schienda, ScM, LGC, and a patient family speaker.